Mancini A, De Marinis L, Calabrò F, Sciuto R, Oradei A, Lippa S, Sandric S, Littarru G P, Barbarino A
Istituti di Endocrinologia, Università Cattolica del Sacro Cuore, Roma, Italy.
J Endocrinol Invest. 1989 Sep;12(8):511-6. doi: 10.1007/BF03350748.
In previous works we have demonstrated that Coenzyme Q10 (CoQ10) levels have a significant inverse correlation with thyroid hormone concentration in patients with spontaneous hyper- or hypothyroidism. In order to verify whether this correlation is maintained in patients on long-term amiodarone therapy, in whom thyroid metabolism is altered by the iodine contained in the drug, we have studied 30 patients with thyroid dysfunction induced by chronic amiodarone treatment. We have distinguished four groups of patients: group A (n = 8): patients with true hyperthyroidism induced by drug administration; group B (n = 11): patients with mild hyperthyroid symptoms, but isolated thyroxine increase or dissociation between different indexes of thyroid function; group C (n = 5): patients with normal thyroid hormone levels, but increased TSH levels; group D (n = 6): patients who appeared really clinically euthyroid, with normal thyroid hormone levels and normal TSH response to TRH. In group A patients, plasma CoQ10 levels averaged 0.49 +/- 0.03 micrograms/ml, significantly lower than those in normal subjects and similar to those observed in spontaneous hyperthyroid patients. In group B patients, CoQ10 levels were in the normal range (0.88 +/- 0.10 microgram/ml). In group C patients, CoQ10 levels were lower than those in normal subjects and similar to those of group A patients (0.49 +/- 0.04 microgram/ml); they differed, in regards to CoQ10 values, in comparison with spontaneous primary hypothyroid patients, who had very high levels of plasma CoQ10. Finally, in group D patients, CoQ10 levels were in the normal range (0.77 +/- 0.04 microgram/ml).(ABSTRACT TRUNCATED AT 250 WORDS)
在先前的研究中,我们已经证明,在自发性甲状腺功能亢进或减退的患者中,辅酶Q10(CoQ10)水平与甲状腺激素浓度呈显著负相关。为了验证在长期服用胺碘酮治疗的患者中这种相关性是否依然存在(这些患者的甲状腺代谢因药物中含有的碘而发生改变),我们研究了30例由慢性胺碘酮治疗引起甲状腺功能障碍的患者。我们将患者分为四组:A组(n = 8):因药物给药导致真正甲状腺功能亢进的患者;B组(n = 11):有轻度甲状腺功能亢进症状,但仅有甲状腺素升高或甲状腺功能不同指标之间出现分离的患者;C组(n = 5):甲状腺激素水平正常,但促甲状腺激素(TSH)水平升高的患者;D组(n = 6):临床检查真正甲状腺功能正常的患者,甲状腺激素水平正常且对促甲状腺激素释放激素(TRH)的TSH反应正常。在A组患者中,血浆CoQ10水平平均为0.49±0.03微克/毫升,显著低于正常受试者,与自发性甲状腺功能亢进患者中观察到的水平相似。在B组患者中,CoQ10水平在正常范围内(0.88±0.10微克/毫升)。在C组患者中,CoQ10水平低于正常受试者,与A组患者相似(0.49±0.04微克/毫升);与血浆CoQ10水平非常高的自发性原发性甲状腺功能减退患者相比,他们在CoQ10值方面存在差异。最后,在D组患者中,CoQ10水平在正常范围内(0.77±0.04微克/毫升)。(摘要截选至250字)